Independent Results Support the Use of BioCurex Technology for Gastric Cancer.

RICHMOND, British Columbia -- BioCurex, Inc. (OTCBB:BOCX) announced today that a group of scientists led by Dr. So Tsuboi from the Shigei Medical Research Hospital, Japan, have published results on the expression of the receptor for AFP (RECAF) in normal, benign and malignant stomach tissue. The tissue study used a variation of the Company's Histo-RECAF kit. The results indicate that RECAF was expressed in 34 out of 47 cancers and not expressed in 59 out of 61 normal or benign tissues. The authors conclude that RECAF may become a new clinically useful marker of gastric cancer.

The paper was published in the peer reviewed international journal Tumor Biology, published by Karger AG. The journal was founded in 1890 for disseminating medical and scientific knowledge.

The other institutions involved in this study were the Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences; the Okayama Citizen's Hospital; and the Oota Memorial Hospital, Fukuyama.

For more information on the article: http://content.karger.com/ProdukteDB/produkte.asp?Aktion= ShowAbstract&ProduktNr=224124&Ausgabe=232278&ArtikelNr=96071. (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

The work was completely independent from BioCurex, which provided, free of cost, the reagents necessary to carry out the work.

Dr. Ricardo Moro, president and CEO, BioCurex, stated: "Stomach cancer in Japan has a higher incidence than in the Western world and it is one of the primary areas of focus for cancer research in that country. This paper reports 73% sensitivity with 97% specificity using Histo-RECAF for tissue examination. Given the small number of samples, the difference in the technique and the distribution of cancer types in Japan compared to the Western hemisphere, the results are consistent with our findings for Serum-RECAF.

This is another example of external validation supporting the potential to use RECAF for diagnosis and perhaps even treatment of cancers. We are discussing the possibility of utilizing and correlating Serum-RECAF in the authors' own laboratories as a prelude to engaging Japanese scientific companies in licensing discussions."

About BioCurex:

BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAF(TM), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.

BioCurex has signed a licensing agreement with Abbott Laboratories for BioCurex's RECAF(TM) Cancer technology as outlined in a joint press release dated March 29, 2005. The release noted that the cancer marker RECAF(TM) has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.

To read more about the Company, please visit the News section in our web site (www.biocurex.com).

Note:

The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.